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Abstract
The antigenic structure of the membrane protein hemagglutinin (HA) from the 2009 A(H1N1) influenza virus was dissected
with a high-throughput screening method using complex antisera. The approach involves generating yeast cell libraries
displaying a pool of random peptides of controllable lengths on the cell surface, followed by one round of fluorescence-
activated cell sorting (FACS) against antisera from mouse, goat and human, respectively. The amino acid residue frequency
appearing in the antigenic peptides at both the primary sequence and structural level was determined and used to identify
‘‘hot spots’’ or antigenically important regions. Unexpectedly, different antigenic structures were seen for different antisera.
Moreover, five antigenic regions were identified, of which all but one are located in the conserved HA stem region that is
responsible for membrane fusion. Our findings are corroborated by several recent studies on cross-neutralizing H1 subtype
antibodies that recognize the HA stem region. The antigenic peptides identified may provide clues for creating peptide
vaccines with better accessibility to memory B cells and better induction of cross-neutralizing antibodies than the whole HA
protein. The scheme used in this study enables a direct mapping of the antigenic regions of viral proteins recognized by
antisera, and may be useful for dissecting the antigenic structures of other viral proteins.
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Introduction
The 2009 A(H1N1) influenza virus, which is also referred to as
the swine-origin influenza virus (S-OIV), caused the first global
influenza pandemic in recent decades [1]. Given continuous
antigenic drift and reassortment of heterotypic influenza viruses
circulating in human and animal reservoirs, global concerns have
been raised regarding an increasing threat of an influenza
pandemic [2]. Current treatment strategies for influenza-A viruses,
such as vaccines and drugs, have not provided broad and lasting
protection, partly due to the constantly evolving nature of the viral
surface glycoprotein, hemagglutinin (HA) that allows it to avoid
host immune attack.
HA is the key viral antigen in determining host specificity and
inducing neutralizing antibody since it plays a major role in
binding to host cell receptors and fusing with host cell membranes
[3]. For many challenging diseases caused by viruses, the
recognition of certain neutralizing epitopes by the immune system
can indeed provide broad and potent protection [4,5]. The
antigenic structure of HA and the corresponding antibody
response are not fully understood, complicating rational design
of vaccines aimed at modulating antibody responses for targeting
key epitopes.
Our previous knowledge of viral antigenic structure was based
mainly on the structure of antibody-antigen complexes or
mutational analysis of related antigenic drifts [6–8]. Recently,
many new approaches have emerged for the rapid extraction of
monoclonal antibodies toward target antigens from antibody
phage display libraries [5,9,10], using direct sorting of memory B
cells [11], or by immortalization of IgG expressing B cells that
reflect the antibody repertoire [12,13]. These methods provide
much more information on viral epitopes, although they are often
laborious. The major alternative approaches for epitope mapping
are derived from scanning with antigenic peptides displayed on the
surface of bacteriophage, bacteria and yeast [14–21], which in
recent years have increasingly incorporated fluorescence-activated
cell sorting (FACS). In these efforts, short defined or random
peptides with a narrow length range (,50 amino acid residues
(aa)) are used to screen against monoclonal or polyclonal
antibodies.
Inspired by advances in cell surface display technology [22,23]
and peptide fragment library construction [24], we devised a high-
throughput scheme that utilizes yeast display and FACS that
allows for direct screening of random viral peptide libraries against
complex antisera instead of isolated antibodies (Zuo T, Shi XL,
Xu WH, Lin Z, and Zhang LQ, unpublished results). The peptide
library is generated by random digestion of the gene encoding the
target viral protein, followed by a PCR-based reassembly step that
results in fragments with controllable lengths (normally in the
range of 100–500 bp) [24]. These peptides are then expressed on
the yeast cell surface by fusion to the yeast adhesion receptor AGA
2 protein, which has previously been used to display defined short
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From the sequences of the antigenic peptides after screening, it is
possible to determine the relative frequency of each amino acid
residue involved in recognition by antisera, and how these residues
are distributed in the three-dimensional structure of HA. Using
this approach, we analyzed the 2009 A(H1N1) influenza virus HA
protein using mouse, goat and human antisera. Unexpectedly,
different antigenic profiles were seen for different antisera.
Moreover, five antigenic regions were identified, four of which
are located in the conserved HA stem region responsible for
membrane fusion. ELISA binding assays and absorption exper-
iments using peptides that encompass these regions have
confirmed their antigenic activities.
Results
Outline of the screening procedure
The procedure for construction, expression and screening of
random viral peptide libraries using yeast surface display is
shown in Fig. S1 (see also Materials and Methods for details). In
step 1, the full length HA gene of the pandemic 2009 A(H1N1)
influenza virus (including the core HA protein of 519 aa, the
signal peptide of 16 aa, and the inter membrane domain of
36 aa) was digested and re-assembled by PCR to form a pool of
fragments enriched in 100–500 bp [24]. In step 2, the fragment
library was ligated into the yeast display vector pCTCON-T
(derived from the yeast surface display vector pCTCON-2 [23]
shown in Fig. 1), transformed into yeast EBY100 cells and
induced for expression, generating a typical library of 1610
5–10
6
clones to cover most of the possible fragments [25]. Because
there are 3 stop codons on pCTCON-T downstream of the
peptide inserts to terminate every ORF, the theoretical
possibility for in-frame fusions is 1/3 for the N-terminal end of
the peptide inserts. Thus, the theoretical yield for cells expressing
in-frame peptides is 1/6 (the fragments can be inserted in
forward and reverse directions).
Subsequently in step 3, the cell library was incubated with
antisera, labeled with secondary fluorescent antibody and
subjected to FACS in step 4, after which the cells harboring
antibody-binding peptides were distinguished from those with
non-binding peptides. In step 5, we isolated plasmids directly from
the pool of yeast cells containing positive peptide sequences, which
were retransformed into E. coli for sequencing. This reduced
laborious plasmid extraction from individual yeast clones.
Plasmids containing in-frame sequences were transformed back
into yeast for individual flow cytometry (FCM) verification.
Retransformation and FCM were also performed for plasmids
containing out of frame sequences (false positive). Antigenic
peptide sequences were aligned with the HA sequence in step 6
(see also Figs. 2 and 3). In step 7, statistical analyses both on the
sequence and structural levels were then performed to map out the
antigenically important regions of the HA protein, by summariz-
ing the frequency of each amino acid residue appearing in the
antigenic peptides (see also Fig. 4).
The HA polypeptide is cleaved into two subunits linked by a
disulfide bond, HA1 and HA2, to form the mature HA trimer.
The majority of the HA1 subunit forms the viral membrane-distal
globular head responsible for receptor binding, whereas the HA2
subunit together with the N- and C- termini of HA1 forms the
membrane-proximal stem region that plays a major role in
membrane fusion. Thus two plasmids, pCTCON-HA1,
pCTCON-HA2, respectively, were constructed to display the
HA1 subunit of 328 aa (residues 17–344 of the HA protein) and
the HA2 ecto-domain of 192 aa (residues 345–536 of the HA
protein) as positive controls for FCM (Fig. 1). The HA1 and HA2
displayed on the yeast surface were recognized by the mouse, goat
and human antisera, and confirmed by FCM (Fig. S2, panels B, E,
and, H; and C, F, and I, respectively).
Figure 1. Vectors constructed in the study. Vector pCTCON-T was derived from pCTCON-2 [23] by inserting an assistant sequence with two Xcm
I sites at both ends between Nhe I and BamH I sites. Digestion of pCTCON-T yielded a T vector for TA ligation with random fragments of the H1N1 HA
gene. ‘Stop’, ‘Stop*’ and ‘Stop**’ stand for three different stop codons for three possible ORFs, respectively. The random peptide library was
expressed under the control of the galactose inducible GAL 1/10 promoter and displayed on the surface of the yeast cells by fusion to the yeast
adhesion receptor AGA 2 protein. Vectors pCTCON-HA1 and pCTCON-HA2, created by inserting HA1 and HA2 genes between the Nhe I, BamH I sites
of pCTCON-2, were used as positive controls in FCM detection.
doi:10.1371/journal.pone.0018016.g001
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antisera immunized with HA protein
We first screened the yeast library displaying the H1N1 HA
peptides to study the murine immune response to recombinant
HA protein of the 2009 A(H1N1) Influenza virus. Freshly induced
library cells were incubated with mixed sera from immunized mice
and subsequently labeled with fluorescent secondary antibodies.
To avoid potential bias introduced by growth advantage of the
yeast cells, only one round of sorting was performed. Plasmids
isolated from positive yeast cells were transformed into E. coli cells
and plated. Single clones (100) were picked randomly and
sequenced, of which 82 (82%) were shown to contain in-frame
inserts. These results indicate that the sorting process is able to
distinguish in-frame sequences from the random library that
contained only 1/6 (16.7%) in-frame inserts efficiently. After
verification of individual peptides by FCM detection, the ratio of
recombinant antigen expressed on the yeast surface (RAYS) was
determined by dividing the mean fluorescence intensity of peptide
expressing yeast cells by the mean fluorescent intensity of the non-
expressing (pCTCON-2) yeast cells [26]. 56 positive clones with a
RAYS ratio $2 were considered as antigenic and analyzed at both
the sequence and structural level [26]. Alignment of positive
peptides with the original HA sequence shows that 87% are in the
HA2 region (95627 aa), with just 13% in the HA1 region
(259626 aa) which cover nearly the entire HA1 protein (Fig. 2,
panel A). The FCM histograms of several representative yeast
clones are shown in Fig. 3, panel A. Clones M-5 (corresponding to
residues 55–313 of HA, or 70 aa shorter than HA1) and M-7
(residues 69–275, or 120 aa shorter than HA1) were strongly
positive (RAYS ratio .5), and contained the entire receptor
binding domain (RBD) and the vestigial esterase domain in the
globular HA head. Clones M-33 (residues 387–489) and M-52
(residues 423–492) displayed much shorter peptides but also
showed strong fluorescent FCM signals (Fig. 3, panel A), albeit
with relatively lower RAYS ratios of 3–4. Judged from the mean
fluorescence intensities, the binding affinities of these displayed
peptides were generally weaker than the whole HA1 (Fig. S2,
panel B).
The sequencing results of the antigenic peptides alone are less
informative (Fig. 2). Nevertheless, when we perform a statistical
analysis by summarizing the normalized frequency of each amino
acid residue in all positive antigenic peptides (defined as the
residue frequency map), a major peak with the full width at half
maximum (FWHM) from residues 387–480 is revealed (Fig. 4,
panel A). We also modify the residue frequency map by taking into
account the respective RAYS ratios of positive peptides, which
however results in an overall rather similar frequency map (Fig.
S3, panel B). Furthermore, even if we combine all the in-frame
sequences from sorted yeast cells, a similar map (Fig. S3, panel C)
is again obtained, implying that the noises from the in-frame but
Figure 2. Alignment of antigenic peptide profiles derived from screening against three antiserum samples. (A) 56 peptides (with a
RAYS ratio $2) obtained using mouse antisera (M-1 to M-56 from top to bottom). (B) 55 peptides obtained using goat antisera with the whole HA
protein (G-1 to G-55 from the top to the bottom). (C) 51 peptides obtained using human plasma (H-1 to H-51 from top to bottom). The coordinates of
the whole HA protein are indicated by the bars. The borders of the HA1 and HA2 regions (residue 345) are indicated by dashed lines.
doi:10.1371/journal.pone.0018016.g002
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wishes to gain a quick view of the ‘‘hot’’ antigenic regions.
The residue frequency map is then overlaid onto the crystal
model of the trimeric HA of the 2009 A(H1N1) influenza virus
(PDB ID: 3LZG) [27], and annotated by colors from red (high
frequency) to blue (low frequency) (Fig. 4, panel B). This structural
frequency map reveals that the major peak (corresponding to
residues 387–480 within the FWHM) on the residue frequency
map can be divided into two dominant antigenic regions since they
have independent structural features. One corresponds to the
central coiled-coil helix CD in the HA2 subunit responsible for
membrane insertion, designated as R1 (residues 424–480,
indicated by red, see also Fig. 5), while the other contains helix
A in the HA2 subunit that is important for conformational change
upon low pH exposure, designated as R2 (residues 387–423,
indicated by faint red and white, see also Fig. 5) [28]. R1 is present
in a relatively recessed surface area while R2 is located near the
exterior surface area of the stem region. For the HA1 subunit, no
distinct antigenic region is identified, because of the limited
number of peptides (7) with relatively longer lengths (all .200 aa),
which are insufficient to form peak areas.
Screening of antigenic peptides recognized by goat
antisera immunized with pandemic 2009 A(H1N1)
influenza virus
We also screened the same yeast library against serum samples
from goats immunized by the 2009 A(H1N1) influenza virus to
examine whether different animal models would yield a similar
profile of antigenic peptides. Following sorting and sequencing,
78/100 clones were confirmed as in-frame, among which 55 tested
positive by the goat anitsera in FCM (RAYS ratio $2).
Surprisingly, alignment of the positive antigenic peptides with
the full HA protein shows a distribution strikingly different from
the alignment obtained using the mouse antisera in several aspects.
First, 78% of the antigenic peptides are located in the HA1 region
and have shorter lengths (54632 aa), while only 9% are in the
HA2 region (96619 aa). Second, 13% of the peptides are in the
region across HA1 and HA2 (66631 aa) (Fig. 2, panel B).
Representative antigenic clones were subjected to FCM. As shown
in Fig. 3, panel B, clones G-15 (residues 38–136 of HA) and G-29
(residues 70–162) in the HA1 region, G-46 (residues 308–339) near
the HA1-HA2 cross region, and G-55 (residues 413–479) in the
HA2 region, all shorter than 100 aa, demonstrated strong
antigenicity (RAYS ratio .5). Judged from the mean fluorescence
intensities, the binding affinities of these displayed peptides were
generally stronger than the whole HA1 (Fig. S2, panel E).
By analyzing the residue frequency map, more peaks are
revealed than those obtained from the mouse anitsera, with the
largest one with its FWHM spanning residues 22–125 with a small
split around residue 60, and a medium one with its FWHM at
residues 303–350 (Fig. 4, panel C, and Fig. S4). In the structural
frequency map (Fig. 4, panel D), the largest peak is composed of
two independent regions: residues 22–60 at the N-terminus of
HA1 adjacent to helix A on HA2, designated as R3; and residues
61–125 located in the vestigial esterase domain of the globular
head, designated as R5 (indicated by two red regions in the
globular head and stem region, respectively, see also Fig. 5) [6].
The antigenic region of the medium peak (residues 303–350)
consists of the C- terminal extension of HA1, designated as R4
(indicated by faint red within the stem region, see also Fig. 5). It
Figure 3. FCM histograms of representative yeast clones. The FCM signal for cells displaying antigenic peptides (the area filled by red color)
overlaid with the FCM signal of non-expressing cells containing pCTCON-2 (the black curve) is shown. The designation of the clones follows the same
order indicated in Fig. 2. The corresponding HA residues for each clone are illustrated. (A) FCM signals for clones M-5, M-7, M-33, and M-52 from
screening against mouse antisera. (B) FCM signals for clones G-15, G-29, G-46 and G-55 from screening against goat antisera. (C) FCM signals for
clones H-1, H-11, H-26 and H-45 from screening against human plasma.
doi:10.1371/journal.pone.0018016.g003
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residue frequency map for the mouse, goat and human antiserum samples, respectively. The x-axis shows amino acid residues of the HA protein. The
y-axis shows the normalized frequency of individual amino acid that appears in the pool of antigenic peptides screened against each antiserum
sample. (B), (D) and (F) illustrate the structural frequency map for the mouse, goat and human antiserum samples, respectively. Both the surface and
backbone structure of the HA trimer of 2009 A(H1N1) virus (PDB ID: 3LZG) are annotated by colors from red to blue, representing a frequency
spectrum from high to low, as shown in the color bar.
doi:10.1371/journal.pone.0018016.g004
Figure 5. The five dominant antigenic regions displayed in stereo view. The HA monomer surface view is shown on the left and colored to
illustrate the five dominant antigenic regions. In order from most membrane proximal to distal: R1 (orange, residues 424–480 of HA) and R2 (yellow,
residues 387–423) in HA2 were determined by screening against mouse and human antisera; R3 (purple, residues 22–60), R4 (green, residues 303–
350), and R5 (cyan, residues 61–125) in HA1 were determined by screening against goat antisera. The HA monomer cartoon view is shown on the
right and follows the same coloring scheme, with the third monomer shown in the back and colored in grey.
doi:10.1371/journal.pone.0018016.g005
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screening also appear in this residue frequency map, although in a
much less dominant manner as illustrated by the small plateau
between the end of R4 and residue 479 (Fig. 4, panel C). Taken
together, the antigenic peptides recognized by the goat antisera are
different from those recognized by the mouse antisera, and in
particular present a more diverse picture of antigenic sites in the
HA1 region.
Screening of antigenic peptides recognized by human
plasma immunized with the 2009 A(H1N1) influenza
vaccine
The screening against human plasma immunized by the 2009
A(H1N1) influenza vaccine was carried out essentially as described
above. Among the 100 sequences obtained after FACS analyses,
74 peptides were found to be in-frame, and 51 were confirmed to
be antigenic (RAYS ratio $2). It is interesting to see that the
distribution of theses peptides is similar to that obtained using the
mouse antisera, with only 4% of peptides in the HA1 region (87
and 37 aa in length), 4% across HA1 and HA2 (96 and 39 aa in
length), and 92% in the HA2 region (100630 aa) (Fig. 2, panel C).
Using FCM, three representative clones, H-11 (residues 359–479
of HA), H-26 (residues 390–480) and H-45 (residues 423–480), all
in the HA2 region, showed strong signals (RAYS ratio .5).
Although only 2 antigenic peptides are in the HA1 region, a clone
expressing H-1 (residues 108–194), which harbored the Sa
antigenic site in RBD of the HA protein, yielded a RAYS ratio
greater than 3 (Fig. 3, panel C). Again, judged from the mean
fluorescence intensities, the binding affinities of these displayed
peptides were generally weaker than the whole HA1 (Fig. S2,
panel H).
The residue frequency map also reveals a major peak (FWHM
at residues 392 to 480). This peak position is similar to that
obtained using the mouse antisera (FWHM at residues 387–480),
resulting in an almost identical structural frequency map (Fig. 4,
panels E and F, and Fig. S5). Thus, these antigenic regions are
considered identical to R1 and R2 obtained from the mouse serum
screening (Fig. 5).
Accessibility of antigenic peptides displayed on yeast cell
surface
The accessibility of short antigenic peptides displayed on the
yeast cell surface [19–21] was confirmed in this study with
fluorescence confocal microscopy, as exemplified by the antigenic
clones G-29 (93 aa) and G-46 (32 aa), from the screening against
the goat antisera (Fig. S6). As shown in the figure, the antigenic
peptides were localized on the outer surface of the membrane, and
well accessible to the antibodies in the complex antisera.
Neutralization assay using yeast cells displaying antigenic
peptides
Three representative yeast clones displaying antigenic peptides
G-15, G-55, and H-11, obtained from the screening against the
goat antisera and human plasma samples, were characterized for
neutralization titers (IC50) by testing protection efficacy to MDCK
cells from the A/reassortant/NYMC X-179A/California/07/
2009(H1N1) exposure. Cells containing pCTCON2 were used
as absorbent controls for evaluation of background IC50 values.
HA1 and HA2 were also incorporated to determine the ability of
the globular head and stem regions to absorb antibodies in the
antisera. As summarized in Table S1, all single clones reduced the
IC50 of the corresponding antisera, demonstrating qualitatively the
neutralization efficacy of these antigenic peptides.
Binding affinities of purified peptides to mouse, goat and
human antisera
To further confirm the antigenic activities of the identified R1–
R5 regions, five newly designed short peptides encompassing
regions R1–R5 (Fig. 6, panel A) were expressed as C- terminal
fusions to thioredoxin (Trx) and purified from E. coli [29,30]. The
binding affinities of these peptides to the mouse, goat and human
antisera were characterized by the method of ELISA, with
thioredoxin as the control (Fig. 6, panels B and D). As can been
seen from the figure, the ELISA results generally correspond well
to the screening results shown in Figs. 4 and 5. Specifically, the
peptide P1 (corresponding to the R1 region identified in all three
screenings, Figs. 4 and 5) was reactive to all three antisera. The
peptides P3, P4 and P5, corresponding to the R3–R5 regions
identified only in the screening against the goat antisera (Fig. 4,
panels C, D, and Fig. 5) were only reactive to the goat antisera
(Fig. 6, panel C). There is one exception in that the peptide P2
(corresponding to the R2 region identified in the screenings using
the mouse and human antisera, Figs. 4 and 5) showed no
measurable affinity to either mouse or human antisera, suggesting
that the R2 region might be less conformation-independent than
the other four regions.
It should be noted that, after subtraction of the background
binding of the negative control protein (Trx), the binding affinity
of the peptide P1 to the human antisera after vaccination increased
only about one fold compared with the antisera before vaccination
(Fig. 6, panel D). This might be contributed to cross-reactive
antibodies to other influenza subtypes pre-existing in the human
serum subjects, given the conservative nature of the P1 sequence
or the R1 region [13].
Discussion
We report here the identification of antigenic peptides of the
2009 A(H1N1) influenza HA protein from a combinational library
of viral protein fragments displayed on the surface of yeast cells
and sorted by FACS. The peptide fragments were constructed in a
way to have a broad but limited range of lengths [24], and
screened using antisera from mouse, goat and human. We then
used a novel statistical approach to identify antigenically important
regions of the viral protein based on the frequency of each residue
appearing in the antigenic peptides at both the primary sequence
and structural level.
This approach reveals interesting antigenic features of the HA
protein. First, the antibody responses to the 2009 A(H1N1) viral
protein HA appear to vary significantly depending on the species,
with the goat response being strikingly different from those of
mouse and human (Fig. 4). These results imply possibly different
immune responses among animal species, and in the case of
human, the specific immunization background may also play a
role [13]. Moreover, the antigenic peptides obtained from the
screening against the mouse or human antisera are predominantly
located in the HA2 region, whereas those from the screening
against the goat antisera are predominantly in the HA1 region.
Second, five antigenically important regions, R1 to R5 in the order
from most membrane proximal to distal (Fig. 5), are identified.
Moreover, except for R5 which is located in the vestigial esterase
domain of the HA globular head, all of the other regions are in the
HA stem region. Among them, R1 and R2 come together to form
a major peak with a FWHM range from residues 387 to 480
(Fig. 4, panels A and E). Although the peptide P2 corresponding to
the R2 region showed no measurable affinity to either mouse or
human antisera (Fig. 6), which suggests that this region might be
more conformation-dependent than the rest four regions, it is
Screening Reveals Unexpected HA Antigenic Regions
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structurally it is distinguishable from the R1 region (Fig. 5), and (2)
several recent studies have reported the epitopes of monoclonal
antibodies targeting H1 subtype HA proteins, which fall into the
R2 region of this study [10,31,32] (see below).
Previously most influenza HA antibodies have been found to
recognize epitopes in the globular head and interfere with binding
to target cells [6–8,33–36], for example, the classical five antigenic
sites (Sa, Sb, Ca1,C a 2, and Cb) [6,7]. However, technically the
monoclonal antibodies used in these previous studies were
obtained from murine hybridoma cells by radioimmunoassay
(RIA) or hemagglutination inhibition (HI) assay. The nature of
these assays favored the isolation of antibodies that bound
predominantly to the globular head of the virus and inhibited
binding of the virus to the host cells. In this current study,
however, complex antisera were used, which should contain
antibodies recognizing other regions of the HA protein. On the
other hand, only one antigenic region (R5) is identified in the
globular head in this study, possibly because the epitopes in this
head region are more conformation-dependent and may require
longer peptides or even a complete domain of HA1 to be displayed
for full antigenicity (at least for the mouse serum and human
plasma samples). It is then noteworthy that the head region,
especially the area around the receptor binding site, contains
mostly beta structures, which more likely require stabilization by
long-range interactions than the helical structures in other regions
of HA (Fig. 5). However, the peptide library constructed in this
study was enriched at 100–500 bp (or less than 170 aa), which was
likely insufficient to map the conformational epitopes. Nonethe-
less, the current screening method is a valuable complementation
to the more classical approaches that are biased toward full HA1
or HA2 domain.
Several recent studies support our findings regarding antigenic
regions R1–R4 in the stem region of HA. In efforts aimed at
characterizing antibodies with cross-neutralizing activity for
various influenza virus subtypes [10,13,31], it was found that
most of these antibodies bind to the HA stem region and interfere
with conformational changes of the protein critical for membrane
fusion. For example, in the case of antibody CR6261 (binding to
HA of the SC1919 virus, H1 type), two antigenic regions on HA
stem were revealed: helix A in the HA2 region, and the adjacent
HA1 region [32]. The critical sites in helix A (corresponding to
residues 390–391, 393–395, 398, 401–402, 405 in H1N1 HA) fall
within the R2 region identified in this study, whereas the
hydrophobic interaction sites in the adjacent HA1 region
(corresponding to residues 38–42, 306–307 in H1N1 HA) fall
into regions R3 and R4 of this study, respectively. More recently, it
was reported that for a different cross-neutralizing antibody that
targets a broad range of H3 subtype virus strains, 12D1, the
dominant contacts on the antigen (corresponding to residues 425–
455 in H1N1 HA) [37] correlate well with the R1 region found in
this study. Furthermore, vaccination in mice using a HA2-based
synthetic peptide mimicking the 12D1 epitope was shown to
provide protection against influenza viruses of H3N2, H5N1, and
H1N1 subtypes [38]. Taken together, our approach should be
useful for dissecting antigenic regions on the HA stem, and
providing clues for designing more potent peptide vaccines in
inducing cross-neutralizing antibodies than the entire HA protein
[32].
Compared with other labor-intensive epitope identification
methods that rely on identifying critical residues in escape mutants
and crystal structures, the method used here gives a direct and
panoramic mapping of the antigenic regions of viral proteins
recognized by antisera in a facile and high-throughput way. Our
approach likely contains an inherent bias for shorter peptides, but
nonetheless complements the more classical approaches that favor
longer antigenic peptides or full antigenic domains. The scanning
of antigenic peptides based on phage, bacterial or yeast surface
display methods has been increasingly used in recent years. Our
approach presents two advantages. First, technically we adopt an
easy-to-implement scheme for generating a controllable size of
peptides and our screening typically involves only one round of
FACS-based sorting, in contrast to multiple rounds of panning or
sorting used in the literature [15,16,18]. Although the latter results
in many repeat sequences, we argue that much information is lost
in the enrichment process. Second and more importantly, since
simple alignment of antigenic peptides with the corresponding
viral protein yields only limited information [15,17,39], we employ
a novel statistical means of summarizing the frequency for each
residue appearing in the antigenic peptides at both the primary
sequence and structural level, which enables a direct mapping of
the antigenic structure of a viral protein. Along this line, it is
interesting to note that, using our statistical approach, we re-
evaluate the highly repeated antigenic peptides identified for the
H5N1 HA protein in a recent report [15]. Several major peaks are
clearly revealed (Fig. S7), which should be useful for further
characterization of the antigenic peptides for H5N1 HA.
Materials and Methods
Materials
Mouse antisera, kindly donated by Dr. Zhonghua Liu, AIDS
Research Center, School of Medicine, Tsinghua University
(Beijing, China), were derived by immunizing mice with 293T-
cell secreted recombinant HA protein from A/California/04/
2009(H1N1) virus. Hyperimmune goat sera, a gift from Dr.
Guoyang Liao, Institute of Medical Biology of Chinese Academy
of Medical Sciences and Peking Union Medical College (Kunm-
ing, China), were raised against a Chinese pandemic strain of 2009
A(H1N1) influenza virus. Human plasma samples were obtained 3
weeks post vaccination with inactivated 2009 A(H1N1) influenza
vaccine, and a mixture of 9 samples with the highest activity
among 110 samples as judged by ELISA. These samples were
provided by Dr. Boping Zhou of Shenzhen East Lake Hospital
(Shenzhen, China), and written informed consent was obtained
from all study participants. All samples were de-identified prior to
analysis, and the protocols were approved by the Institutional
Review Board (IRB) of Shenzhen East Lake Hospital. All viral
strains are closely related.
Restriction enzymes and DNA polymerases were purchased
from New England Biolabs (Beverly, MA) or Takara (Dalian,
China). DNase I was obtained from Worthington (Lakewood, NJ).
Fluorescence-labeled secondary antibodies were purchased from
Invitrogen (Shanghai, China) or Santa Cruz Biotechnology (Santa
P5 (blue arrows), in relation to the five antigenic regions R1–R5. The coordinate of the HA protein is indicated by the grey bar, with the five antigenic
regions represented in the same color as in Fig. 5. The peptides P1–P5 were expressed as C- terminal fusions to the thioredoxin (Trx) tag. Binding
activities of the peptides against the mouse (B), goat (C) and human (D) antisera before and after immunization were characterized by the method of
ELISA, with the Trx protein as the negative control. The x-axis shows the dilution ratios of corresponding antiserum samples. The y-axis shows the
absorbance at 450 nm after development with the substrate 3,39,5,59-tetramethylbenzidine (TMB).
doi:10.1371/journal.pone.0018016.g006
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Takara. The kits for DNA purification, gel recovery, plasmid
miniprep and A-Tailing modification were obtained from Tiangen
(Beijing, China) or Takara (Dalian, China). The kit for yeast
plasmid DNA isolation was from Omega Biotech (Victoria BC,
Canada). Sequencing was performed by Invitrogen or by
SinoGenoMax (Beijing, China). Escherichia. coli DH5a was
obtained from Takara. Yeast strain Saccharomyces cerevisiae
EBY100 was obtained from Invitrogen.
Construction of yeast surface display vectors
The pCTCON-2 yeast display vector was kindly provided by
Prof. Dane Wittrup [23]. The DNA fragments coding the HA1
and HA2 proteins were amplified from plasmid CMV-R-Cali-04-
09 carrying the whole HA gene of A/California/04/2009(H1N1)
virus, provided by Prof. Paul Zhou, Institute Pasteur of Shanghai,
Chinese Academy of Sciences (Shanghai, China). DNA fragments
were digested and inserted between the Nhe I and BamH I sites of
pCTCON-2, resulting in the plasmid pCTCON-HA1 and
pCTCON-HA2. The primers used for HA1 and HA2 amplifica-





and BamH I sites are in bold and italic).
Two Xcm I restriction sites (CCANNNNN/NNNNTGG) were
introduced between Nhe I and BamH I sites of pCTCON-2 to
create pCTCON-T. Digestion of pCTCON-T by Xcm I restriction
nuclease and gel extraction yielded the T-vector with two 39 T
overhangs. Random fragments with 39 A tails were inserted
between the two Xcm I sites by T-A ligation.
Preparation of HA fragment library
The gene coding for the full HA protein of A/California/04/
2009(H1N1) virus was amplified from plasmid CMV-R-Cali-04-
09 with the forward primer 59-CGCCACCATGAAGGC-
TATCC-39 and reverse primer 59-TTAGATGCAGATTCTG-
CACTG-39. Detailed procedures for fragmentation and reassem-
bly were described previously, except that PhusionH high-fidelity
polymerase (NEB) was used in reassembly [24]. The reassembled
DNA samples were purified and modified to add 59 A overhangs
by an A-Tailing Kit (Takara). The backbone vector pCTCON-T
was digested with Xcm I and purified with a Tiangen gel
purification kit to reduce self-ligation. The gene fragments and
backbone vector were ligated at 16uC for 16 h and then
electroporated into E. coli DH5a competent cells for propagation.
The plasmid library was then isolated and used to transform yeast
EBY100 cells by the Li-Ac method [40]. Expression of peptide
libraries on yeast EBY100 cells was performed as reported by
Wittrup’s group [23]. Transformed yeast cells were grown for 24 h
at 30uC with shaking in SDCAA medium (yeast nitrogen-based
casamino acid medium containing 20 g?L
21 glucose) and passed
one time into fresh medium to eliminate dead cells. The library
cells were then centrifuged, resuspended in SGCAA medium
(yeast nitrogen-based casamino acid medium containing 20 g?L
21
galactose) to an OD600 value of 0.5–1 and induced at 20uC for 36–
48 h with shaking.
Fluorescence labeling, FACS-based screening and
characterization of antigenic peptides
Prior to yeast library screening, nonspecific interactions of
serum samples (i.e., mouse, goat or human antisera) with yeast
proteins were removed by incubation with induced yeast cells
carrying the control vector pCTCON-2. To label cells for FACS,
1610
7 (For yeast EBY1001 cells, OD600<1610
7 cells/mL) freshly
induced library cells were pelleted at 8,000 g for 1 min in a
1.5 mL microcentrifuge tube and washed two times with 1 mL of
16Phosphate Buffered Saline (PBS). Cells were then incubated
with 100 mL of pre-absorbed serum (1:50 diluted in PBS) at 4uC
for 1 h. Unbound antibodies were removed by washing two times
with 1 mL of PBS. The library cells were incubated with 1–2 mgo f
fluorescein isothiocyanate (FITC) or phycoerythrin (PE) labeled
secondary antibodies in 100 mLa t4 uC for 45 min. After washing
two times with PBS, cells were resuspended in 1 mL of PBS and
loaded onto a BD-FACS AriaII
TM machine (Shanghai, China) for
sorting. Yeast cells harboring the pCTCON-2 vector were
processed as described above and used as a negative control.
The positive gate was set to exclude all negative control cells
(,0.1% leakage). The total amount of cells used for sorting was
adjusted to ensure that more than 1610
5 cells could be harvested,
which were then collected in 5 mL of SDCAA medium and grown
overnight at 30uC with shaking.
After one passage of library cells into fresh medium,
heterogeneous plasmid DNA was isolated from the library and
transformed into E. coli DH5a cells. For each library, a total of 100
colonies were randomly picked from the plates and sequenced
using a pair of primers (pCTCON2-Seq-For: 59-GTTCCAGAC-
TACGCTCTGCAGG-39 and pCTCON2-Seq-Rev: 59-GTTC-
CAGACTACGCTCTGCAGG-39). The plasmids carrying gene
fragments inserted in-frame with the original HA gene were re-
transformed into yeast EBY100 cells, induced, and labeled as
described for FCM detection on a BD-FACS Calibur cytometer
(Shanghai, China). The ratio of recombinant antigen expressed on
the yeast surface (RAYS) was determined by dividing the mean
fluorescence intensity of peptide expressing yeast cells by the mean
fluorescence intensity of the non-expressing (pCTCON-2) yeast
cells. Clones with a RAYS ratio $ 2 were considered positive and
the corresponding peptide sequences were selected for further
analysis [26].
Fluorescence Confocal Microscopy
Yeast cells containing plasmids for displaying antigenic peptides
were grown at 30uC for 24 h in SDCAA medium and induced at
20uC for 36 h in SGCAA medium. 1610
7 cells were harvested by
centrifugation, incubated with goat antisera (1:100 diluted in
100 mL of PBS) and labeled with 1 mg of FITC conjugated anti-
goat IgG secondary antibody as described above. Labeled cells
were resuspended to 5610
7 cells/mL, fixed with 4% paraformal-
dehyde and photographed on a Zeiss 710 laser scanning confocal
microscopy (Carl Zeiss, Germany) at the Center of Biomedical
Analysis, Tsinghua University. Yeast cells containing non-
expressing vector pCTCON-2 and HA1-expressing vector
pCTCON-HA1 were treated in the same way as negative and
positive controls, respectively.
ELISA assays for purified representative peptides against
three antisera
Five peptides newly designed to encompass the regions R1–R5
were expressed as fusions to the C- terminus of thioredoxin (Trx)
and purified from E. coli, using a modification of the self-cleaving
elastin-like polypeptide tag method (ELP) (with purity over 80% as
judged by SDS-PAGE) [29,30]. For comparison, the Trx tag was
used as the negative control. When mouse and goat antisera were
employed as the first antibody, the wells were coated with 100 ng
of peptides or Trx. But for human antisera, 10 ng of peptides or
Trx control was used to decrease the background signal caused by
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PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e18016unspecific interactions between the human antisera and the trace
impurities from E. coli cells. After blocking with 10% Fetal Bovine
Serum (FBS) diluted in 16PBS with 0.25% Tween-20 (PBST),
serial dilutions were added to each well and incubated for 1 h at
37uC, followed by addition of 1:5,000 diluted HRP-conjugated
secondary antibody. Assays were developed by adding 100 mLo f
3,39,5,59-tetramethylbenzidine (TMB) substrate solution and the
reactions were stopped with 50 mLo fH 2SO4 (1 M). The assays
were carried out in duplicates and each well was washed 4 times
with PBST between steps. The absorbance at 450 nm was
recorded on a SpectroMAX 190 Microtiter reader (Molecular
Devices, CA).
Neutralization assay
Prior to the Neutralization assay, 500 mL antisera (diluted 1:50, and
pre-absorbed with induced yeast cells carrying the control vector
pCTCON-2) were mixed with freshly induced yeast cells (1610
8)
displaying specific antigenic peptides on surface. After incubation at
4uC for 12 h, the mixtures were centrifuged at 8,000 g for 1 min and
supernatants mixed with another batch of freshly induced yeast cells.
This process was repeated four times, and then the supernatants were
used for determining the neutralization titers, using a microneutraliza-
tion assay with A/reassortants/NYMC X-179A/California/07/
2009(H1N1) virus and MDCK cells according to standard procedures
[41]. Briefly, triplicate serial dilutions (1:50 to 1:1600) of antiserum
samples were incubated with 100 50% tissue culture infective dose
(TCID50)o fv i r u sf o r2ha t3 5 uC prior to adding MDCK cells. Cells
were incubated at 35uC for 72 h, and the half maximal inhibitory
concentration (IC50) was determined. All the neutralization assays
were performed at the AIDS Research Center, School of Medicine,
Tsinghua University following standard procedures.
Supporting Information
Figure S1 Schematic outline of the screening approach.
In Step 1, the gene encoding the viral protein H1N1 HA was
amplified, digested and re-assembled to generate the fragment
library (the red and grey segments indicate the antigenic and non-
antigenic peptides, respectively). In Step 2, the fragment library
was ligated into the display vector pCTCON-T, transformed into
yeast cells and induced for expression. In Step 3, the yeast cells
expressing random peptides were incubated with antisera and
fluorescence-labeled second antibodies and subjected to FACS in
Step 4. Afterward in Step 5, the gene fragments were isolated from
the sorted cells and sequenced. The in-frame sequences were re-
transformed into yeast cells and verified by FCM detection
individually. In Step 6, an antigenic peptide profile was extracted
for the sequences corresponding to the antigenic peptides, based
on which the residue frequency and structural frequency maps
were derived in Step 7.
(TIF)
Figure S2 FCM detection of HA1 and HA2 displayed on
yeast. Panels A, D, and G show FCM histograms of yeast cells
expressing negative control vector pCTCON-2 stained with
mouse antisera (and labeled by anti-Mouse IgG FITC), goat
antisera (labeled by anti-Goat IgG FITC), and human plasma
samples (labeled by anti-Human IgG PE), respectively. HA1
positive controls are similarly shown in panels B, E and H, and
HA2 positive controls in panels C, F and I.
(TIF)
Figure S3 Statistical analyses of peptides from screen-
ing against mouse antisera. (A) Frequency map for each
residue appearing in the 56 positive antigenic peptides (RAYS
ratio $2). This figure is same as Fig. 4, panel A. (B) Frequency
map for each residue appearing in the 56 positive antigenic
peptides, but weighted by the respective RAYS ratio. (C)
Frequency map for each residue appearing in all 82 in-frame
peptides sorted from the library before they were individually
verified by FCM.
(TIF)
Figure S4 Statistical analyses of peptides from screen-
ing against goat antisera. (A) Frequency map for each residue
appearing in the 55 positive antigenic peptides (RAYS ratio $2).
The figure is same as Fig. 4, panel C. (B) Frequency map for each
residue appearing in the 55 positive antigenic peptides, but
weighted by the respective RAYS ratio. (C) Frequency map for
each residue appearing in all 78 in-frame peptides sorted from the
library before they were individually verified by FCM.
(TIF)
Figure S5 Statistical analyses of peptides from screen-
ing against human plasma. (A) Frequency map for each
residue appearing in the 51 positive antigenic peptides (RAYS
ratio $2). The figure is same as Fig. 4, panel E. (B) Frequency map
for each residue appearing in the 51 positive antigenic peptides,
but weighted by the respective RAYS ratio. (C) Frequency map for
each residue appearing in all 74 in-frame peptides sorted from the
library before they were individually verified by FCM.
(TIF)
Figure S6 Fluorescence confocal microscopic images of
yeast cells displaying antigenic peptides. Binding of the
antibodies in the goat antisera to the yeast cells displaying the
control vector pCTCON-2 (A), HA1 (B), and antigenic peptides
G-29 (C), G-46 (D) (see also Fig. 3, panel B) were visualized by
using a FITC-labeled anti-goat IgG secondary antibody. The
lengths of the antigenic peptides are shown in brackets.
(TIF)
Figure S7 Statistical analyses of antigenic peptides
based on the phage panning results shown by Khurana
et al. [15]. The x-axis represents all H5N1 HA amino acid
residues. The y-axis shows the normalized frequency of individual
residue appearing in the 784 antigenic peptides (39 unique
sequences) obtained from panning against H5N1 avian influenza
convalescent sera. The six clusters (I–VI) defined by Khurana et al.
are graphically represented below the x-axis. Several representa-
tive antigenic peptides are also shown as green arrows (numbered
according to Khurana et al.). Even though the antigenic peptides
were enriched multiple times during the screening process and
thus these peptides are less diverse and might be biased in
sequences, several peaks are clearly identifiable, and predomi-
nantly in the HA2 region.
(TIF)
Table S1 H1N1 virus neutralization assay.
(DOC)
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